BACKGROUND: Little is known about clinical implementation of medical abortion in the United States following approval of mifepristone as an abortifacient by the Food and Drug Administration (FDA) in 2000. We collected information regarding medical abortion practices of National Abortion Federation (NAF) members for the year 2001. METHODS: Questionnaires were mailed to 337 active US NAF member facilities. RESULTS: A total of 258 facilities responded (77%); 252 nonhospital facilities were included in the analysis. Most of these facilities (87%) offered medical abortion in 2001, providing an estimated 28,400 medical abortions, approximately 52% of medical abortions in the US that year. Over 75% began offering mifepristone/misoprostol abortions within 5 months of the start of mifepristone distribution. Almost all (99%) reported using mifepristone/misoprostol regimens, with most offering one or more evidence-based alternative regimens (83%); a few (4%) used the FDA-approved regimen. CONCLUSION: After FDA approval of mifepristone, NAF member facilities rapidly adopted evidence-based mifepristone/misoprostol regimens.
BACKGROUND: Little is known about clinical implementation of medical abortion in the United States following approval of mifepristone as an abortifacient by the Food and Drug Administration (FDA) in 2000. We collected information regarding medical abortion practices of National Abortion Federation (NAF) members for the year 2001. METHODS: Questionnaires were mailed to 337 active US NAF member facilities. RESULTS: A total of 258 facilities responded (77%); 252 nonhospital facilities were included in the analysis. Most of these facilities (87%) offered medical abortion in 2001, providing an estimated 28,400 medical abortions, approximately 52% of medical abortions in the US that year. Over 75% began offering mifepristone/misoprostol abortions within 5 months of the start of mifepristone distribution. Almost all (99%) reported using mifepristone/misoprostol regimens, with most offering one or more evidence-based alternative regimens (83%); a few (4%) used the FDA-approved regimen. CONCLUSION: After FDA approval of mifepristone, NAF member facilities rapidly adopted evidence-based mifepristone/misoprostol regimens.
Authors: Edith R Guilbert; Althea S Hayden; Heidi E Jones; Katharine O'Connell White; E Steven Lichtenberg; Maureen Paul; Wendy V Norman Journal: Can Fam Physician Date: 2016-04 Impact factor: 3.275
Authors: Wendy V Norman; Edith R Guilbert; Christopher Okpaleke; Althea S Hayden; E Steven Lichtenberg; Maureen Paul; Katharine O'Connell White; Heidi E Jones Journal: Can Fam Physician Date: 2016-04 Impact factor: 3.275
Authors: Ian M Bennett; Margaret Baylson; Karin Kalkstein; Ginger Gillespie; Scarlett L Bellamy; Joan Fleischman Journal: Ann Fam Med Date: 2009 Nov-Dec Impact factor: 5.166
Authors: Daniel A Grossman; Kate Grindlay; Todd Buchacker; Joseph E Potter; Carl P Schmertmann Journal: Am J Public Health Date: 2012-11-15 Impact factor: 9.308
Authors: Ushma D Upadhyay; Katrina Kimport; Elise K O Belusa; Nicole E Johns; Douglas W Laube; Sarah C M Roberts Journal: PLoS One Date: 2017-07-26 Impact factor: 3.240
Authors: Courtney Devane; Regina M Renner; Sarah Munro; Édith Guilbert; Sheila Dunn; Marie-Soleil Wagner; Wendy V Norman Journal: Pilot Feasibility Stud Date: 2019-11-08
Authors: Heidi E Jones; Katharine O'Connell White; Wendy V Norman; Edith Guilbert; E Steve Lichtenberg; Maureen Paul Journal: PLoS One Date: 2017-10-12 Impact factor: 3.240